Clinical trials: Intestinal Metaplasia
Gastric Cancer, Gastric Intestinal Metaplasia
Chemoprevention of Gastric Carcinogenesis
A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO) in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk regions of Latin America.
- Trial name
- NCT02794428
- Testing
- Eflornithine
- Where
- 2 sites in Honduras, Puerto Rico
- Volunteers
- 91 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Barrett's Esophagus
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
This study is designed to evaluate the effect of dexlansoprazole once daily (QD) and twice daily (BID) dosing on the recurrence of intestinal metaplasia (IM) in participants who achieved complete eradication of Barrett's…
- Trial name
- NCT02162758
- Testing
- Dexlansoprazole
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Takeda
Barrett Esophagus
HALO Patient Registry: Ablation of Barrett's Esophagus
The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD).
- Trial name
- NCT00848237
- Testing
- Radiofrequency Ablation (HALO Ablation Systems)
- Where
- United States
- Volunteers
- 5,521 people
- Sponsor
- Medtronic - MITG
Chronic Atrophic Gastritis, Gastric Carcinoma
Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
This randomized phase IIb trial studies how well curcumin works in preventing gastric cancer in patients with chronic atrophic gastritis and/or gastric intestinal metaplasia.
- Trial name
- NCT02782949
- Testing
- Curcumin, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 2 sites in Honduras, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Barrett Esophagus
Ablation of Intestinal Metaplasia Containing Dysplasia
The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing…
- Trial name
- NCT00282672
- Testing
- Ablation System plus anti-secretory medication
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- Medtronic - MITG
Stomach Neoplasms, Metaplasia
Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia
The presence and the extent of gastric intestinal metaplasia(IM) is a good indicator of high risk group of gastric cancer. Many methods was developed to survey it, including multiple gastric biopsy or methylene blue…
- Trial name
- IM (NCT01499576)
- Testing
- Acetic acid chromoendoscopy
- Where
- South Korea
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Konyang University Hospital
Barrett Esophagus
Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years
This study was conducted in 2 serial phases (dosimetry phase and effectiveness phase) to evaluate a balloon-based ablation device (HALO360) that delivers a pre-set amount of energy density (J/cm2) to barrett's tissue.
- Trial name
- AIM (NCT00489268)
- Testing
- HALO Ablation System
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- Covidien, GI Solutions